香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 截至2025年6月30日止六個月之中期業績公告 董事會欣然公佈本集團截至2025年6月30日止六個月之未經審核綜合中期業績， 連同截至2024年6月30日止六個月之比較數字，已經審計委員會審閱。 於本公告內，「我們」及「我們的」指本公司及（倘文意另有所指）本集團。本公 告所載若干金額及百分比數據已因約整進行調整，或已約整至一個或兩個小 數位。任何表格、圖表或其他地方中總額與當中所列金額總和之間的任何差異 乃因約整所致。 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至6月30日止六個月 | | | | | 2025年 | 2024年 | 變動 | | | 人民 ...

Core Viewpoint - The surgical robotics market is undergoing significant changes, particularly in China, where local companies are breaking through in technology development, clinical application, and business models, leading to a transformation in the industry [6][11]. Group 1: Market Dynamics - The global surgical robotics market has been dominated by Intuitive Surgical's "da Vinci" system, which has created substantial technical and commercial barriers [7][8]. - The high price of the "da Vinci" system, approximately 30 million RMB per unit, has limited access for many medical institutions in China [8][9]. - Local companies are entering the market by offering surgical robots at about one-third the price of the "da Vinci" system, making them more accessible [9]. Group 2: Investment Trends - From 2020 to 2022, the Chinese surgical robotics industry saw nearly 100 financing events, with disclosed total funding exceeding 20 billion RMB [12]. - The market is characterized by high technical barriers, high growth potential, and high profit margins, with projections indicating the market could reach 3.84 billion USD by 2026, growing at a rate of 44.3% [13]. Group 3: Challenges and Adjustments - Despite the growth potential, the industry is facing a cooling trend in capital investment, with only nine financing events reported in 2024 [19]. - The lengthy procurement process in hospitals and limited insurance coverage for robotic surgeries are significant barriers to market penetration [23][24]. - The lack of a clear mechanism for medical accident liability is causing hospitals to be cautious in adopting robotic surgeries [26]. Group 4: Strategic Shifts - Companies are moving away from price competition and focusing on differentiated innovation to build core competitiveness [29]. - Many firms are targeting lower-tier cities for market expansion, with a notable increase in installations in county-level hospitals [32]. - International expansion is becoming a crucial growth strategy, with companies like MicroPort and Jingfeng Medical successfully securing overseas orders [35]. Group 5: Future Outlook - The current cooling of capital is viewed as a new starting point for the industry, indicating a shift towards maturity rather than a downturn [36]. - Companies that focus on long-term value and balance technology, clinical application, and commercialization are likely to succeed in the competitive landscape of high-end medical equipment [37].

Core Viewpoint - The global surgical robot market is undergoing significant changes, particularly in China, where local companies are breaking through in technology development, clinical application, and business models, leading to a transformation in the industry [4][8]. Market Dynamics - The surgical robot market was previously dominated by Intuitive Surgical's "da Vinci" system, which held about 60% of the global market share, creating high barriers to entry and elevated prices for end-users [3][5]. - The price of a single "da Vinci" device is approximately 30 million RMB, with high annual maintenance costs, making it unaffordable for many medical institutions [5]. - Domestic companies are entering the market by offering surgical robots at about one-third the price of "da Vinci," marking a shift from "following" to "running alongside" in the competitive landscape [7][8]. Investment Trends - From 2020 to 2022, the Chinese surgical robot industry saw nearly 100 financing events, with disclosed total financing exceeding 20 billion RMB, indicating strong investor interest [8]. - The market is characterized by high technical barriers, growth potential, and profitability, with a projected market size of 3.84 billion USD by 2026, growing at a rate of 44.3% [9]. Challenges and Adjustments - Despite the growth potential, the industry is experiencing a cooling in capital markets, with fewer financing events in 2024 compared to previous years, attributed to macroeconomic factors and a shift in investor focus towards certainty [10][13]. - The lengthy procurement process in hospitals and limited insurance coverage for robotic surgeries are significant barriers to market penetration [15][16]. Strategic Shifts - Companies are moving away from price competition to focus on differentiated innovation to build core competitiveness, as stability in product performance is prioritized by top hospitals [18]. - Many companies are targeting lower-tier cities for market expansion, supported by government policies that simplify approval processes and promote equipment distribution to grassroots medical institutions [20]. International Expansion - Increasingly, domestic surgical robot companies are looking to international markets for growth, as established markets like Europe and the US have more developed payment systems and procurement decision-making processes [21][22]. - For instance, MicroPort achieved a revenue of 257 million RMB in 2024, with a year-on-year growth of 146%, and significant international orders [23]. Conclusion - The cooling of capital is viewed not as a "winter" but as a new starting point for industry maturation, where companies that focus on long-term value and balance technology, clinical application, and commercialization will succeed in the competitive landscape of high-end medical equipment [24].

Investment Rating - The report does not explicitly state an investment rating for the laparoscopic surgical robot industry Core Insights - The laparoscopic surgical robot industry is characterized by high technological barriers, long R&D cycles, and strict regulatory oversight, with significant growth driven by domestic breakthroughs and reduced procurement costs. The competitive landscape is expected to evolve towards a "duopoly + niche specialization" model in the long term [4][41][42] Industry Overview - Laparoscopic surgical robots combine endoscopic technology with robotic systems, primarily used in urology, gynecology, and general surgery, offering advantages such as minimal invasiveness and rapid recovery [4][5] - The industry is classified into two main categories based on surgical techniques: multi-port and single-port laparoscopic surgical robots [5] Industry Characteristics - The industry features long R&D cycles and strict regulatory requirements, with the registration process for high-risk medical devices typically taking over five years [6][7] - High levels of industry collaboration are evident, with the integration of precision manufacturing, sensor control, image recognition, and biomaterials [8] - The technological complexity and high patent protection create significant barriers to entry, with a focus on multi-disciplinary collaboration and sustained capital investment [9] Development History - The industry has evolved through three stages: the embryonic phase (1985-2000), the initiation phase (2000-2021), and the rapid development phase (2021-present), with significant advancements in technology and market acceptance [10][11][12][13][15] Market Size and Growth - The market size for laparoscopic surgical robots in China was approximately 3.12 billion RMB in 2022, projected to reach 9.84 billion RMB by 2026, with a CAGR of 33.3% [37][38] - The growth is attributed to domestic production breakthroughs that significantly lower procurement costs, leading to increased hospital purchases [38][39] Competitive Landscape - The market is witnessing an influx of domestic companies, with over 10 models approved for market entry by the end of 2024, leading to intensified competition and potential market consolidation [41] - A high-end competitive landscape is emerging, with established players like Intuitive Surgical's da Vinci system dominating the market, while domestic brands like MicroPort's TiMai are gaining traction [42] Supply Chain Analysis - The supply chain consists of upstream component suppliers, midstream manufacturers, and downstream clinical applications, with the performance of upstream components directly impacting the overall system capabilities [16][17] - The midstream segment is critical, with leading manufacturers focusing on system integration and production, while the downstream segment involves hospital procurement and clinical application [19][30] Conclusion - The laparoscopic surgical robot industry is poised for rapid growth, driven by technological advancements, regulatory support, and increasing acceptance among healthcare providers, with a clear trend towards domestic innovation and market diversification [40][41]

格隆汇8月18日丨微创机器人-B(02252.HK)宣布，公司谨定于2025年8月28日（星期四）举行董事会会 议，以考虑及通过（其中包括）本集团截至2025年6月30日止六个月的中期业绩及公布，并考虑派发中 期股息（如有），以及处理其他事项。 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 於本公告日期，執行董事為何超博士、房聰女士及劉雨先生；非執行董事為孫洪斌先生及陳 琛先生；以及獨立非執行董事為李明華博士、姚海嵩先生及鍾偉文先生。 上海微創醫療機器人（集團）股份有限公司（「本公司」與其附屬公司合稱「本集 團」）董事（「董事」）會（「董事會」）茲通告，本公司謹定於2025年8月28日（星期四） 舉行董事會會議，以考慮及通過（其中包括）本集團截至2025年6月30日止六個 月的中期業績及公佈，並考慮派發中期股息（如有），以及處理其他事項。 承董事會命 上海微創醫療機器人（集團）股份有限公司 主席 孫洪斌先生 中國上海，2025年8月18日 董事會會議召開日期 ...

Group 1 - The Hong Kong stock market showed strong performance on August 13, with the Hang Seng Index rising by 1.88% and the Hang Seng Tech Index increasing by 2.35%, particularly driven by the healthcare sector [1] - The Hong Kong Innovative Drug 50 ETF (513780) closed up by 3.38% with a turnover rate exceeding 18% and a transaction volume of over 400 million yuan, indicating strong investor interest [1] - Notably, the Hong Kong Innovative Drug 50 ETF (513780) experienced a net inflow of 1.07 billion yuan over the past 15 trading days, and it has gained over 92% year-to-date as of August 12 [1] Group 2 - The National Healthcare Security Administration announced the preliminary review results for the 2025 medical insurance directory and commercial insurance innovative drug directory, with 534 drugs passing the basic medical insurance directory review and 121 drugs passing the commercial insurance innovative drug directory review [2] - High-priced innovative drugs, including CAR-T therapies, are seeking inclusion in the commercial insurance innovative drug directory, indicating a push for diversified payment methods for innovative drugs [2] - Analysts suggest that the rise of innovative drugs is sustainable, recommending attention to companies with rich pipeline layouts, high-potential single innovative drugs, and leading technology platforms in the sector [2]

Core Viewpoint - The third Global Medical Robotics Conference 2025, themed "MedRobot Next | Next Stop Technology Future," focuses on the systematic upgrade of intelligent surgical systems, the construction of a full-chain ecosystem, and global pathways in the surgical robotics industry [5][7]. Event Details - The event will take place on September 5-6, 2025, at the Zhongguancun Innovation Demonstration Zone Exhibition Center in Beijing [7]. - Pre-registration is free, and attendees will receive discount codes upon the opening of the registration system [2]. Participating Companies - Confirmed participants include manufacturers from various surgical robotics sectors such as minimally invasive robots, orthopedic robots, ophthalmic robots, and vascular intervention robots [2][5]. Conference Themes - The conference will cover several key themes, including: - **Technological Systems and Intelligent Evolution** [8] - **Commercialization and Hospital System Implementation** [8] - **Global Strategy and International Expansion Paths** [9] Key Topics of Discussion - The conference will address critical topics such as: - AI integration in surgical robots to enhance autonomy and system collaboration [10] - The challenges of integrating surgical robots with hospital systems [10] - Global market comparisons and commercialization pathways for surgical robots [10] - The importance of building a sustainable and credible robot brand recognized by doctors [10] - The exploration of day surgery and grassroots market opportunities for robotic solutions [10] Awards and Recognition - The MedRobot annual awards have become one of the most anticipated technical awards in the Chinese medical robotics field, recognizing significant contributions and innovations [16]. Industry Insights - The conference aims to redefine the future of hospitals through robotic technology, emphasizing the need for collaboration among manufacturers, component suppliers, algorithm developers, and clinical teams [17].

Market Overview - The A-share market showed strong performance with the Shanghai Composite Index steadily rising, while the Hong Kong stock market experienced a narrow fluctuation, closing up by 0.03% [1] - Concerns in the market are heightened due to the U.S. President Trump's shortened ultimatum for sanctions against Russia, now set at 10 days, with potential impacts on India and other countries [1] - The U.S. is also set to impose significant tariffs on semiconductor chips and pharmaceuticals, with drug tariffs reaching as high as 250% [1] Company Developments - Jingtai Technology announced a pipeline cooperation agreement with DoveTree worth approximately HKD 470 billion (USD 59.9 billion), leading to a stock surge of over 12% [2] - A-share company Weixin New Materials faced regulatory scrutiny after a stock price surge related to the "embodied intelligent robot" concept and control change expectations [2] - The Shanghai government released a plan for the development of the embodied intelligence industry, aiming for breakthroughs in core algorithms and technologies by 2027 [2] Industry Trends - The 2025 World Robot Conference is set to showcase over 100 new products, nearly double from last year, indicating a growing interest in robotics [3] - The U.S. student loan delinquency rate has reached 12.9%, the highest in 21 years, which may influence Federal Reserve decisions on interest rates [3] - The steel and paper industries are experiencing positive momentum, with companies like Maanshan Steel and Nine Dragons Paper seeing significant stock price increases [3] Defense Sector Insights - The military industry is gaining traction with significant contracts, such as the sale of the Hongqi-9 air defense system and the export of submarines to Pakistan [4] - China Shipbuilding Defense announced a profit increase of 213.25% to 267.73% for the first half of the year, leading to a stock rise of nearly 8% [4] Consumer Market Activity - The new consumption sector is becoming active, with companies like Pop Mart seeing increased attention at recent toy exhibitions [5] - The liquor industry is also responding to market trends, with new product launches and stock price increases [5] Aviation Sector Developments - Cathay Pacific announced an $8.1 billion order for 14 Boeing 777-9 aircraft, marking its first deal with Boeing in 12 years, despite concerns over the safety record of Boeing aircraft [7] - The long delivery timeline for the 777-9 model raises potential issues regarding aircraft aging and maintenance [7] Energy Sector Updates - The State Grid reported record electricity usage due to high temperatures, with peak load reaching 1.233 billion kilowatts, an increase of 53 million kilowatts from last year [8] - Coal prices have risen significantly, impacting the steel industry, which is maintaining high production levels [8] Automotive Sector Performance - XPeng Motors reported a record monthly delivery of 36,717 vehicles in July, a year-on-year increase of 229.4% [10] - The company is expanding its presence in Europe, with significant sales growth and new model launches [11][12]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海微创医疗机器人（集团）股份有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | ...